Skip to main content
. 2016 Jul 26;185(3):361–371. doi: 10.1111/cei.12803

Figure 6.

Figure 6

Leukadherin‐1 (LA1) modulates monocyte inflammatory cytokine secretion. Using cytometric bead array we showed that LA1 pretreatment reduced the interkeukin (IL)‐1b, IL‐6 and tumour necrosis factor (TNF) release in monocyte cultures stimulated with (a) Toll‐like receptor (TLR)‐7/8 agonist R848 (n = 18) and (b) TLR‐2 agonist Pam3csk4 (n = 11). We also showed that LA1 pretreatment (c) increased the IL‐12 release but did not affect the IL‐10 release by monocyte cultures stimulated with TLR‐7/8 agonist R848 (n = 18) and (d) increased the IL‐10 and IL‐12 release by monocyte cultures stimulated with TLR‐2 agonist Pam3csk4 (n = 11). Data presented in (a) and (b) are mean ± standard error of the supernatant concentration in pg/ml at 18 h, and statistical testing by paired t‐test. Data presented in (c) and (d) are median ± interquartile range of the supernatant cytokine concentration in pg/ml at 18 h, and statistical testing by Wilcoxon's matched‐pairs test. Dimethylsulphoxide (DMSO) provides the carrier control for LA1.